Posaconazole
Posaconazole 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute Lymphoblastic Leukaemia、Acute Myeloid Leukaemia、Higher-risk Myelodysplastic Syndromes。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
20 项
全球在招研究
3 项
已进入 III/IV 期
24 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- AstraZeneca
- Chinese PLA General Hospital
- First Affiliated Hospital of Zhejiang University
- Beat AML, LLC
- University of Alabama at Birmingham
- Melbourne Health
- Amphista Therapeutics Ltd
- Institute of Hematology & Blood Diseases Hospital, China
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、澳大利亚、加拿大、丹麦、德国、意大利、日本、South Korea、英国、比利时、法国
正在招募患者的 Posaconazole 研究
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
II 期招募中中国NCT06928376Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
I 期 / II 期招募中美国澳大利亚加拿大丹麦NCT07155226Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
III 期招募中中国NCT07396480Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
II 期 / III 期招募中美国NCT03013998Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
I 期招募中美国NCT07044544Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
IV 期招募中澳大利亚NCT03717623Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
I 期招募中美国NCT07723703Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases
不适用招募中中国NCT07135778Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
不适用招募中中国NCT07183878Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
II 期招募中中国NCT06802757A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
II 期招募中美国NCT06859424PTX3-targeted Antifungal Prophylaxis
不适用招募中比利时法国瑞士NCT03828773Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)
II 期招募中法国NCT06541067Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
不适用招募中中国NCT07185503Imetelstat Combinations in Relapsed AML
I 期招募中美国NCT07320235FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
I 期招募中美国NCT07283094Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
II 期招募中美国比利时GreeceIsraelNCT04665037A Study of BGB-11417 in Participants With Myeloid Malignancies
I 期 / II 期招募中美国澳大利亚中国法国NCT04771130Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
I 期 / II 期招募中美国NCT06129734A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
I 期 / II 期招募中美国比利时加拿大法国NCT04988555
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。